Ascendis Pharma AS (ASND)
NASDAQ · Healthcare · Biotechnology
Ascendis Pharma AS is a Healthcare company with a market capitalization of $16.14B and a trailing P/E ratio of 28.1.
5-Year Price History
Latest Annual Financials · FY ending December 31, 2025 · in EUR
Recent Quarterly Earnings (EPS)
| Quarter | Reported | Actual EPS | Estimate | Surprise |
|---|---|---|---|---|
| Q1 2026 | May 7, 2026 | $0.27 | $0.43 | -37.2% |
| Q4 2025 | February 11, 2026 | $-0.55 | $-0.24 | -129.2% |
| Q3 2025 | November 12, 2025 | $-1.00 | $-0.12 | -733.3% |
| Q2 2025 | August 7, 2025 | $-0.93 | $-1.42 | +34.5% |
| Q1 2025 | May 1, 2025 | $-1.58 | $-1.51 | -4.6% |
| Q4 2024 | February 12, 2025 | $-0.64 | $-1.17 | +45.3% |
Short Interest
FINRA-reported short interest for semi-monthly settlement dates, published about nine business days after each settlement. Share counts are adjusted to the current split basis.
| Settlement | Shares Short | % of Shares Out | Days to Cover | Change |
|---|---|---|---|---|
| July 15, 2026 | 3,104,151 | 4.81% | 5.6 | -5.3% |
| June 30, 2026 | 3,277,898 | 5.08% | 2.5 | +65.0% |
| June 15, 2026 | 1,987,044 | 3.08% | 3.5 | +15.5% |
| May 29, 2026 | 1,720,143 | 2.67% | 3.1 | -0.1% |
| May 15, 2026 | 1,721,179 | 2.67% | 2.8 | -39.2% |
| April 30, 2026 | 2,832,689 | 4.61% | 3.1 | -22.5% |
| April 15, 2026 | 3,654,940 | 5.95% | 5.6 | -1.1% |
| March 31, 2026 | 3,695,502 | 6.02% | 9.5 | -4.0% |
Other Biotechnology Stocks
Frequently Asked Questions
What is Ascendis Pharma AS's market cap?
As of August 13, 2026, Ascendis Pharma AS (ASND) has a market capitalization of $16.14B.
What is Ascendis Pharma AS's P/E ratio?
Ascendis Pharma AS trades at a trailing price-to-earnings (P/E) ratio of 28.1. Its forward P/E is 15.4.
Does Ascendis Pharma AS pay a dividend?
Ascendis Pharma AS does not currently pay a dividend.
What sector is ASND in?
Ascendis Pharma AS is in the Healthcare sector, specifically the Biotechnology industry.
What is Ascendis Pharma AS's short interest?
As of the July 15, 2026 FINRA settlement, 3,104,151 ASND shares were sold short, or 4.81% of shares outstanding. Days to cover: 5.6. FINRA publishes short interest twice a month, about nine business days after each settlement date.
What was Ascendis Pharma AS's revenue?
In its latest reported fiscal year (ending December 31, 2025), Ascendis Pharma AS reported revenue of 691.71M EUR and net income of -219.03M EUR.
Ask your own questions about ASND
Try mrmarket.ai freeData as of August 13, 2026. Figures are sourced from company filings and market data and may be delayed or revised. For informational purposes only — not investment advice.